Solid Biosciences Climbs After Multiple Trial Updates

Dow Jones

Jan 15

By Katherine Hamilton

Shares of Solid Biosciences rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug.

The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months.

Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said.

The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said.

Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia.

The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The drug is the first investigational gene therapy for the neurodegenerative disorder.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 14, 2026 11:39 ET (16:39 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603964824"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603964824\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603964824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 00:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603964824","market":"fut","top_or_hot":-1,"title":"Solid Biosciences Climbs After Multiple Trial Updates","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug. \n</p>\n<p>\n  The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months. \n</p>\n<p>\n  Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said. \n</p>\n<p>\n  The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said. \n</p>\n<p>\n  Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia. \n</p>\n<p>\n  The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The drug is the first investigational gene therapy for the neurodegenerative disorder. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Solid Biosciences Climbs After Multiple Trial Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSolid Biosciences Climbs After Multiple Trial Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-15 00:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/SLDB\">Solid Biosciences</a> rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug. \n</p>\n<p>\n  The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months. \n</p>\n<p>\n  Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said. \n</p>\n<p>\n  The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said. \n</p>\n<p>\n  Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia. \n</p>\n<p>\n  The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The drug is the first investigational gene therapy for the neurodegenerative disorder. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:39 ET (16:39 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603964824","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603964824","pubTimestamp":1768408740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Solid Biosciences rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug.The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months.Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said.The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said.Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia.The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The d","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLDB":"Solid Biosciences"},"translate_title":"Solid Biosciences在多次试验更新后攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLDB":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Shares of Solid Biosciences rose after the life-sciences company provided updates on multiple continuing trials, including dosing initiation and a fast-track designation in the U.S. for one drug. \n\n\n  The stock advanced 7.2%, to $5.53, late Wednesday morning. Shares are still down 13% over the past three months. \n\n\n  Solid Biosciences dosed 33 participants in a Phase 1/2 clinical trial for SGT-003, a treatment for Duchenne muscular dystrophy. The treatment continues to be generally well tolerated, the company said. \n\n\n  The Charlestown, Mass., company also activated clinical-trial sites for a Phase 1b trial evaluating SGT-501 for the treatment of the heart condition catecholaminergic polymorphic ventricular tachycardia, it said. \n\n\n  Solid Biosciences said Monday it had dosed the first participant in a Phase 1b trial for SGT-212, a drug designed to treat Friedreich's ataxia. \n\n\n  The Food and Drug Administration granted SGT-212 orphan-drug, rare-pediatric-disease and fast-track designations, the company said. The drug is the first investigational gene therapy for the neurodegenerative disorder. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 11:39 ET (16:39 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}